Recombinant gallid herpesvirus 3 (MDV serotype 2) vectors expressing antigens of avian pathogens and uses thereof

The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.

Recombinant HVT vectors expressing antigens of avian pathogens and uses thereof

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors. 1. A recombinant herpesvirus of turkeys (HVT) vector comprising:a first heterologous polynucleotide encoding a first avian pathogen antigen; anda second heterologous polynucleotide encoding a second avian pathogen antigen,wherein the first and the second heterologous polynucleotides are linked by IRES or P2A.2. The vector of claim 1 , wherein the first and second avian pathogen antigens are each claim 1 , independently claim 1 , an Infectious Bursal Disease Virus (IBDV) VP2 antigen claim 1 , an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen claim 1 , or a Newcastle Disease Virus F (NDV-F) antigen.3. The vector of claim 1 , wherein the first and second avian pathogen antigens are each claim 1 , independently claim 1 , an IBDV VP2 antigen having at least 80% sequence identity to SEQ ID NO: 2 claim 1 , an ILTV gD antigen having at least 80% sequence identity to SEQ ID NO: 17 claim 1 , or a NDV-F antigen having at least 80% sequence identity to SEQ ID NOs: 5 and/or 22.4. The vector of claim 1 , wherein the first and second heterologous polynucleotides each comprise claim 1 , independently claim 1 , a nucleotide sequence encoding an IBDV VP2 antigen that has at least 70% sequence identity to SEQ ID NO: 1 claim 1 , a nucleotide sequence encoding an ILTV gD antigen that has at least 70% sequence identity to SEQ ID NO: 16 claim 1 , or a nucleotide sequence encoding a NDV-F antigen that has at least 70% sequence identity to SEQ ID NOs: 3 claim 1 , 4 or 215. The vector of claim 1 , wherein the first heterologous polynucleotide is operably linked to a mCMV IE ...

RECOMBINANT GALLID HERPESVIRUS 3 (MDV SEROTYPE 2) VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF

The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.

RECOMBINANT HVT VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors. 1. A composition or vaccine comprising one or more recombinant herpesvirus of turkeys (HVT) vectors comprising at least one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen.2. The composition or vaccine of claim 1 , wherein the HVT vector comprises a heterologous polynucleotide coding for and expressing a Newcastle Disease Virus F (NDV-F) antigen having at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO:2 claim 1 , 4 claim 1 , 6 claim 1 , 33 claim 1 , 35 claim 1 , or 37.3. The composition or vaccine of claim 2 , wherein the polynucleotide encoding the NDV-F polypeptide is operably linked to a promoter selected from the group consisting of SV40 promoter claim 2 , MDV gB promoter and guinea pig CMV promoter.4. The composition or vaccine of claim 3 , wherein the polynucleotide encoding the NDV-F polypeptide is operably linked to an SV40 polyA signal.5. The composition or vaccine of claim 4 , wherein the polynucleotide encoding the NDV-F polypeptide claim 4 , the operably linked promoter claim 4 , and the SV40 polyA signal are inserted in the IG1 locus of HVT genome.6. The composition of claim 1 , wherein the composition further comprises a second recombinant HVT vector comprising a heterologous polynucleotide coding for and expressing IBDV VP2 antigen.7. The composition of claim 6 , wherein the second recombinant HVT vector is vHVT13.8. The composition of or claim 6 , wherein the composition further comprises one or more recombinant ...

Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof

The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.

RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors. 1. A composition or vaccine comprising one or more recombinant herpesvirus of turkeys (HVT) vectors comprising at least one or more heterologous polynucleotides encoding at least one antigen of an avian pathogen.2. The composition or vaccine of claim 1 , wherein the HVT vector comprises:1) two heterologous polynucleotides, and wherein the first polynucleotide comprises a polynucleotide encoding a polypeptide selected from the group consisting of an Infectious Bursal Disease Virus (IBDV) VP2 antigen, an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen and a Newcastle Disease Virus F (NDV-F) antigen, and wherein the second polynucleotide comprises a polynucleotide encoding a polypeptide selected from the group consisting of an Infectious Bursal Disease Virus (IBDV) VP2 antigen, an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen and a Newcastle Disease Virus F (NDV-F) antigen; or2) a heterologous polynucleotide encoding a polypeptide selected from the group consisting of an Infectious Bursal Disease Virus (IBDV) VP2 antigen, an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen and a Newcastle Disease Virus F (NDV-F) antigen.3. The composition or vaccine of claim 1 , wherein the Infectious Bursal Disease Virus (IBDV) VP2 antigen has at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO:2.4. The composition or vaccine of claim 1 , wherein the Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen has at least 80% sequence identity to the amino acid sequence as set forth ...

RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors. 1. A method of inducing a protective immune response in an animal against an avian pathogen , comprising:administering to the animal an effective amount of a vaccine comprising a recombinant herpesvirus of turkeys (HVT) vector comprising a first heterologous polynucleotide coding for and expressing an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen,wherein the ILTV gD antigen has at least 80% sequence identity to SEQ ID NO:17, the first heterologous polynucleotide has at least 70% sequence identity to SEQ ID NO:16, or both.2. The method of claim 1 , wherein the ILTV gD antigen has at least 95% sequence identity to SEQ ID NO:17.3. The method of claim 1 , wherein the first heterologous polynucleotide has at least 95% sequence identity to SEQ ID NO:16.4. The method of claim 1 , wherein the first heterologous polynucleotide is operably linked to an mCMV IE promoter claim 1 , an SV40 promoter claim 1 , an HHV3gB promoter claim 1 , or a reverse HHV3gB promoter.5. The method of claim 1 , wherein the first heterologous polynucleotide is inserted in the IG1 locus and/or SORF-US2 locus of the HVT genome.6. The method of claim 1 , wherein the first heterologous polynucleotide is operably linked to an mCMV IE or an SV40 promoter at the 5′ end claim 1 , and IRES or P2A at the 3′ end.7. The method of claim 1 , wherein the vaccine further comprises a pharmaceutically or veterinarily acceptable carrier claim 1 , excipient claim 1 , vehicle claim 1 , and/or adjuvant.8. The method of claim 1 , wherein the animal is an avian.9. The method of claim 1 , wherein the HVT ...

RECOMBINANT HVT VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors. 134-. (canceled)35. A composition or vaccine comprising one or more recombinant herpesvirus of turkeys (HVT) vectors , wherein at least one HVT vector comprises two or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen.36. The composition or vaccine of claim 35 , wherein the HVT vector comprises a heterologous polynucleotide coding for and expressing a Newcastle Disease Virus F (NDV-F) polypeptide claim 35 , one or more Infectious Bursal Disease Virus (IBDV) VP2 polypeptides claim 35 , or a combination thereof.37. The composition or vaccine of claim 36 , wherein the NDV-F polypeptide has at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO:2 claim 36 , 4 claim 36 , 6 claim 36 , 33 claim 36 , 35 claim 36 , or 37.38. The composition or vaccine of claim 36 , wherein the IBDV VP2 polypeptide has at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO:8 or 42.39. The composition or vaccine of claim 36 , wherein the HVT vector comprises a heterologous polynucleotide coding for and expressing an Newcastle NDV-F polypeptide having at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO:2 claim 36 , 4 claim 36 , 6 claim 36 , 33 claim 36 , 35 claim 36 , or 37 and one or two heterologous polynucleotides coding for and expressing one or two IBDV VP2 polypeptides having at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO:8 or 42.40. The composition or vaccine of ...

Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof

Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof

Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof

Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

RECOMBINANT HVT VECTORS EXPRESSING ANTIGENES OF VEHICLE PATH pathogens AND APPLICATIONS THEREOF

Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them

Recombinant HVT Vectors Expressing Avian Pathogen Antigens and Uses thereof

Composición o vacuna que comprende un primer vector de virus del herpes de pavo (HVT) recombinante que comprende un polinucleótido heterólogo que codifica y expresa un antígeno del virus de la enfermedad de Newcastle F (NDV-F) unido operativamente a un promotor de SV40 y una señal de poliA de SV40, además en el que el polinucleótido que codifica el polipéptido NDV-F, el promotor de SV40 unido operativamente y la señal de poliA de SV40 se insertan en el locus del sitio intergénico 1 (IG1) del genoma de HVT, además en el que el polinucleótido que codifica y expresa NDV-F tiene la secuencia que se establece en la SEQ ID NO: 1; y un segundo vector de HVT recombinante que comprende un polinucleótido heterólogo que codifica y expresa un antígeno del virus de la enfermedad de bursitis infecciosa (IBDV) VP2, en el que el segundo vector de HVT recombinante es vHVT13. Composition or vaccine comprising a first recombinant turkey herpes virus (HVT) vector comprising a heterologous polynucleotide that encodes and expresses a Newcastle disease virus F (NDV-F) antigen operably linked to an SV40 promoter and an SV40 polyA signal, further wherein the polynucleotide encoding the NDV-F polypeptide, the operably linked SV40 promoter, and the SV40 polyA signal are inserted into the intergenic site 1 (IG1) locus of the HVT genome , furthermore wherein the polynucleotide encoding and expressing NDV-F has the sequence established in SEQ ID NO: 1; and a second recombinant HVT vector comprising a heterologous polynucleotide that encodes and expresses an infectious bursal disease virus (IBDV) VP2 antigen, wherein the second recombinant HVT vector is vHVT13.

Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them.

Vectores recombinantes de herpesvirus de pavo (HVT) que contienen y expresan antígenos de patógenos de aves, composiciones que comprenden los vectores recombinantes de HVT y vacunas polivalentes que comprenden los vectores recombinantes de HVT. La presente invención provee además métodos de vacunación contra diversos patógenos de aves y un método para producir los vectores recombinantes de HVT.

Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων

Η παρούσα εφεύρεση παρέχει ανασυνδυασμένους φορείς ιού του έρπητα από γαλοπούλες (HVT) οι οποίοι περιέχουν και εκφράζουν αντιγόνα παθογόνων των πτηνών, συνθέσεις οι οποίες περιλαμβάνουν τους ανασυνδυασμένους HVT φορείς, πολυσθενή εμβόλια τα οποία περιλαμβάνουν τους ανασυνδυασμένους HVT φορείς και έναν ή περισσότερους αγρίου τύπου ιούς ή ανασυνδυασμένους φορείς. Η παρούσα εφεύρεση περαιτέρω παρέχει μεθόδους εμβολιασμού έναντι μιας ποικιλίας παθογόνων των πτηνών και μέθοδο παραγωγής των ανασυνδυασμένων HVT φορέων.

Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων

Η παρούσα εφεύρεση παρέχει ανασυνδυασμένους φορείς ιού του έρπητα από γαλοπούλες (HVT) οι οποίοι περιέχουν και εκφράζουν αντιγόνα παθογόνων των πτηνών, συνθέσεις οι οποίες περιλαμβάνουν τους ανασυνδυασμένους HVT φορείς, πολυσθενή εμβόλια τα οποία περιλαμβάνουν τους ανασυνδυασμένους HVT φορείς και έναν ή περισσότερους αγρίου τύπου ιούς ή ανασυνδυασμένους φορείς. Η παρούσα εφεύρεση περαιτέρω παρέχει μεθόδους εμβολιασμού έναντι μιας ποικιλίας παθογόνων των πτηνών και μέθοδο παραγωγής των ανασυνδυασμένων HVT φορέων.

Recombinant adenoviral feline leukemia virus vaccine and use thereof

The present invention is directed to recombinant adenoviruses comprising one or more feline leukemia virus (FeLV) genes, and to their use as vaccines. Non-limiting examples of the FeLV genes include those that encode surface glycoproteins such as envelope (Env), and/or structural viral proteins such as Gag.